PSIVIDA CORP. (NASDAQ:PSDV) Files An 8-K Other Events
On June13, 2017, pSivida Corp. issued a press release announcing
that the Companys second Phase3 clinical trial of Durasert
three-year treatment for posterior segment uveitis achieved the
trials primary efficacy endpoint. A copy of the press release
making such announcement is furnished as Exhibit99.1 hereto.
Item9.01 Financial Statements and Exhibits
|99.1||Press release dated June13, 2017|
About PSIVIDA CORP. (NASDAQ:PSDV)
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.